Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14): doi: /jama Study FlowThe number of patients screened for enrollment in the study was not documented. Figure Legend:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14): doi: /jama Kaplan-Meier Estimates of Disease-Free and Overall SurvivalA, Median disease-free survival was 13.4 months (95% CI, months) in the gemcitabine group compared with 6.7 months (95% CI, months) in the observation group (hazard ratio, 0.55 [95% CI, ]). B, Median overall survival was 22.8 months (95% CI, months) in the gemcitabine group compared with 20.2 months (95% CI, months) in the observation group (hazard ratio, 0.76 [95% CI, ]). Vertical lines on curves indicate patients censored on the date of their last follow-up. Figure Legend:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14): doi: /jama Disease-Free and Overall SurvivalSize of data markers indicates the amount of statistical information in the respective subgroup. Figure Legend: